EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

Bianca Serio, Francesco Grimaldi, Lucia Ammirati, Mario Annunziata, Giovanna De Santis, Alessandra Perrotta, Danilo De Novellis, Valentina Giudice iD, Denise Morini, Gabriella Storti, Catello Califano, Antonio Maria Risitano und 2 weitere

Cancer Reports · 2024

DOI: 10.1002/cnr2.2044 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Reports, 2024. Verfasst von Bianca Serio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy. Hauptthemen laut MEDLINE: Gemtuzumab, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Program of the Department of Medicine, Surgery and Dentistry, University of Salerno.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gemtuzumab‐ozogamycin (GO) is approved in combination with high‐dose chemotherapy for treatment‐naïve low‐ and intermediate‐risk acute myeloid leukemia (AML).

Aims

In this retrospective real‐life multicenter study, we reported efficacy and safety of GO plus high‐dose chemotherapy in newly diagnosed AML patients. Methods and Results A total of 31 fit low‐ and intermediate‐risk AML patients treated with GO‐based regimens were retrospectively included in this real‐life multicenter study, and results were compared with a control cohort treated with 3 + 7 alone. Complete remission (CR) rate after induction was 77%, and most responders (45%) underwent two GO‐based consolidation, and minimal residual disease (MRD) negativity was observed in 17 cases (55%) after the end of consolidation. Low genetic risk was associated with increased CR rate compared with intermediate‐risk AML (88% vs. 33%; p < .001), as well as prolonged overall survival (OS; hazard ratio, 0.16; 95% confidential interval, 0.02–0.89; p < .001). GO addition resulted in a survival benefit for low‐risk AML (median OS not reached vs. 25 months; p = .19) while not for intermediate‐risk subjects (10 vs. 13 months; p = .92), compared with the control group. Moreover, GO‐treated patients experienced fever of unknown origin or sepsis in 42% or 36% of cases, respectively, with one death during induction due to septic shock, with similar rates compared with the control group ( p = .3480 and p = .5297, respectively). No cases of veno‐occlusive disease after allogeneic transplantation were observed.

Conclusions

Our real‐life multicenter study confirmed GO‐based treatment efficacy with high MRD negativity rates in fit newly diagnosed AML patients, especially in those with low genetic risk and core binding factor, while limited benefits were observed in intermediate‐risk AML. However, further validation on larger prospective cohorts is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemtuzumabLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedCytarabineRemission InductionNeoplasm, ResidualTreatment OutcomeYoung AdultAminoglycosides

Stichwörter der Autor:innen

acute myeloid leukemiachemotherapyefficacysafety

Substanzen

GemtuzumabCytarabineAminoglycosides

Autor:innen und Institutionen

  • Hematology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Hematology Unit, Department of Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
  • Hematology Unit, Hospital "A. Tortora", Pagani, Italy.
  • Hematology Unit, Hospital "S. G. Moscati", Aversa, Italy.
  • Hematology Unit, Hospital "S. Giuseppe Moscati", Avellino, Italy.
  • Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy.

ORCID-Profile: Valentina Giudice

Förderung

  • Intramural Program of the Department of Medicine, Surgery and Dentistry, University of Salerno

Zitieren

APA

Serio, B., Grimaldi, F., Ammirati, L., Annunziata, M., De Santis, G., Perrotta, A., De Novellis, D., Giudice, V., Morini, D., Storti, G., Califano, C., Risitano, A. M., Pane, F., & Selleri, C. (2024). Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients. Cancer Reports. https://doi.org/10.1002/cnr2.2044

Vancouver

Serio B, Grimaldi F, Ammirati L, Annunziata M, De Santis G, Perrotta A, et al. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients. Cancer Reports. 2024. doi:10.1002/cnr2.2044

BibTeX
@article{Serio2024,
  author = {Serio, Bianca and Grimaldi, Francesco and Ammirati, Lucia and Annunziata, Mario and De Santis, Giovanna and Perrotta, Alessandra and De Novellis, Danilo and Giudice, Valentina and Morini, Denise and Storti, Gabriella and Califano, Catello and Risitano, Antonio Maria and Pane, Fabrizio and Selleri, Carmine},
  title = {Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2044}
}
Kostenlos starten →